31-45 of 123
Kappa-Opioid Settings: Real-World Evidence Insights
MinuteCE®Kappa-Opioid Settings: Real-World Evidence Insights
Improving Sleep and Mental Health in Patients with CKD-aP
MinuteCE®Improving Sleep and Mental Health in Patients with CKD-aP
CKD-aP or Something Else? Decoding the Diagnosis
MinuteCE®CKD-aP or Something Else? Decoding the Diagnosis
- advertisement
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
CME/CEReal-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
CME/CEOptimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
The Clinical Weight of TTR: What the Latest Data Reveal
CME/CEThe Clinical Weight of TTR: What the Latest Data Reveal
Optimizing IgAN Care: Achieving Lower Proteinuria Targets With Combination Therapy
CME/CEOptimizing IgAN Care: Achieving Lower Proteinuria Targets With Combination Therapy
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
CME/CEOptimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
- advertisement
Expert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection
CME/CEExpert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection
Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
CME/CENonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
CME/CEPractical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure











































































